(Total Views: 542)
Posted On: 02/02/2025 8:30:54 PM
Post# of 149929
Glaxosmithkline IPF study --
This was GSK's Phase 1:
GSK3915393 is a small molecule currently being investigated as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF), and according to available information, a Phase 1 clinical trial has already been completed in healthy volunteers to assess its safety and tolerability, primarily focusing on drug interactions with grapefruit juice and the antifungal medication itraconazole.
Key points about GSK3915393 in Phase 1:
Target mechanism:
This drug works by targeting transglutaminase-2 (TG2).
Study population: Healthy volunteers were used in the Phase 1 trial.
Primary focus:
Evaluating the safety profile of the drug, including potential interactions with other medications.
Current status: Phase 1 trials have been completed, and further studies are likely needed to assess its efficacy in treating IPF patients.
__
Only in Phase 2:
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) was last updated on Jan 20, 2025.
ctv.veeva.com/study/a-study...
Through Max post our CCL4 results:
*GSK buys our PF/IPF rights?
Fund to market & royalties.
*Gates Vascular site for trials.
IPF kills 1m a year.
Other than healthy volunteers were used in GSK trial & Leronlimab is the non-toxic of unmet needs: actual CCL4 results coming.
& LL will/would have a (+) combo effect ?
What are the neurological side effects of itraconazole?
Peripheral neuropathy, paresthesia, hypoesthesia, headache, dizziness, tinnitus, transient/permanent hearing loss, dysgeusia, and tremor have also been reported during post-marketing experience. Sep 6, 2024
& I just babbled Friday about LL not having shown any post-trial FDA issues.
Wow.
Think Max has GSK's IPF ear ?
I do.
This was GSK's Phase 1:
GSK3915393 is a small molecule currently being investigated as a potential treatment for Idiopathic Pulmonary Fibrosis (IPF), and according to available information, a Phase 1 clinical trial has already been completed in healthy volunteers to assess its safety and tolerability, primarily focusing on drug interactions with grapefruit juice and the antifungal medication itraconazole.
Key points about GSK3915393 in Phase 1:
Target mechanism:
This drug works by targeting transglutaminase-2 (TG2).
Study population: Healthy volunteers were used in the Phase 1 trial.
Primary focus:
Evaluating the safety profile of the drug, including potential interactions with other medications.
Current status: Phase 1 trials have been completed, and further studies are likely needed to assess its efficacy in treating IPF patients.
__
Only in Phase 2:
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF) was last updated on Jan 20, 2025.
ctv.veeva.com/study/a-study...
Through Max post our CCL4 results:
*GSK buys our PF/IPF rights?
Fund to market & royalties.
*Gates Vascular site for trials.
IPF kills 1m a year.
Other than healthy volunteers were used in GSK trial & Leronlimab is the non-toxic of unmet needs: actual CCL4 results coming.
& LL will/would have a (+) combo effect ?
What are the neurological side effects of itraconazole?
Peripheral neuropathy, paresthesia, hypoesthesia, headache, dizziness, tinnitus, transient/permanent hearing loss, dysgeusia, and tremor have also been reported during post-marketing experience. Sep 6, 2024
& I just babbled Friday about LL not having shown any post-trial FDA issues.
Wow.
Think Max has GSK's IPF ear ?
I do.
(7)
(0)Scroll down for more posts ▼
